<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9732337
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     10
    </month>
    <day>
     28
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     10
    </month>
    <day>
     28
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0959-8138
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       317
      </volume>
      <issue>
       7160
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Sep
       </month>
       <day>
        12
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    </articletitle>
    <pagination>
     <medlinepgn>
      703-13
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of &lt;150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) with less tight control aiming at a blood pressure of &lt;180/105 mm Hg.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      20 hospital based clinics in England, Scotland, and Northern Ireland.
     </abstracttext>
     <abstracttext label="SUBJECTS" nlmcategory="METHODS">
      1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P&lt;0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.
     </abstracttext>
    </abstract>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic beta-Antagonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Angiotensin-Converting Enzyme Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antihypertensive Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Blood Glucose
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      29122-68-7
     </registrynumber>
     <nameofsubstance>
      Atenolol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      62571-86-2
     </registrynumber>
     <nameofsubstance>
      Captopril
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Ophthalmology. 1989 Oct;96(10):1501-10
     </refsource>
     <pmid version="1">
      2587045
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      CMAJ. 1992 Sep 1;147(5):697-712
     </refsource>
     <pmid version="1">
      1521215
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1992 Feb 15;304(6824):405-12
     </refsource>
     <pmid version="1">
      1445513
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Chem. 1992 Nov;38(11):2294-9
     </refsource>
     <pmid version="1">
      1424127
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1998 Sep 12;317(7160):713-20
     </refsource>
     <pmid version="1">
      9732338
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1998 Jun 13;351(9118):1755-62
     </refsource>
     <pmid version="1">
      9635947
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1998 Mar 14;316(7134):823-8
     </refsource>
     <pmid version="1">
      9549452
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Ophthalmol. 1998 Mar;116(3):297-303
     </refsource>
     <pmid version="1">
      9514482
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Intern Med. 1997 Nov 24;157(21):2413-46
     </refsource>
     <pmid version="1">
      9385294
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br Med J (Clin Res Ed). 1987 Jun 6;294(6585):1443-7
     </refsource>
     <pmid version="1">
      3111583
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetes. 1974 Feb;23(2):105-11
     </refsource>
     <pmid version="1">
      4359625
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetologia. 1984 Feb;26(2):109-15
     </refsource>
     <pmid version="1">
      6201409
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Hum Nutr Appl Nutr. 1982 Oct;36(5):378, 380, 382 passim
     </refsource>
     <pmid version="1">
      6292137
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1996 Jan 4;334(1):13-8
     </refsource>
     <pmid version="1">
      7494564
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1995 Oct 21;346(8982):1080-4
     </refsource>
     <pmid version="1">
      7564792
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabet Med. 1994 Nov;11(9):899-909
     </refsource>
     <pmid version="1">
      7705030
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabet Med. 1994 Oct;11(8):773-82
     </refsource>
     <pmid version="1">
      7851072
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabet Med. 1994 Jul;11(6):534-44
     </refsource>
     <pmid version="1">
      7955969
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1994 Dec 15;121(12):912-8
     </refsource>
     <pmid version="1">
      7978716
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Intern Med. 1994 Apr;235(4):297-316
     </refsource>
     <pmid version="1">
      8151262
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br Med Bull. 1994 Apr;50(2):272-98
     </refsource>
     <pmid version="1">
      8205459
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetologia. 1991 Dec;34(12):877-90
     </refsource>
     <pmid version="1">
      1778353
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1990 Apr 7;335(8693):827-38
     </refsource>
     <pmid version="1">
      1969567
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Intern Med. 1991 Jun;151(6):1141-7
     </refsource>
     <pmid version="1">
      2043016
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1991 Jun 26;265(24):3255-64
     </refsource>
     <pmid version="1">
      2046107
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1991 Nov 23;338(8778):1281-5
     </refsource>
     <pmid version="1">
      1682683
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eye (Lond). 1989;3 ( Pt 6):764-7
     </refsource>
     <pmid version="1">
      2630360
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Prev Med. 1985 May;14(3):312-35
     </refsource>
     <pmid version="1">
      2865725
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetologia. 1993 Oct;36(10):1021-9
     </refsource>
     <pmid version="1">
      8243850
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Hypertens. 1993 Mar;11(3):309-17
     </refsource>
     <pmid version="1">
      8387089
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Hypertens. 1993 Mar;11(3):319-25
     </refsource>
     <pmid version="1">
      8387090
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetes Care. 1993 Feb;16(2):434-44
     </refsource>
     <pmid version="1">
      8432214
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetes Metab. 1996 Feb;22(1):64-76
     </refsource>
     <pmid version="1">
      8697298
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1996 Nov 28;335(22):1636-42
     </refsource>
     <pmid version="1">
      8929360
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1996 Dec 18;276(23):1886-92
     </refsource>
     <pmid version="1">
      8968014
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):667-8
     </refsource>
     <pmid version="1">
      10215366
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):667; author reply 668
     </refsource>
     <pmid version="1">
      10215365
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):667; author reply 668
     </refsource>
     <pmid version="1">
      10215364
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2000 Mar 18;320(7237):732
     </refsource>
     <pmid version="1">
      10720342
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2002 Apr 6;324(7341):849; author reply 849-50
     </refsource>
     <pmid version="1">
      11936161
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):666-7; author reply 668
     </refsource>
     <pmid version="1">
      10066218
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1998 Sep 12;317(7160):693-4
     </refsource>
     <pmid version="1">
      9732334
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1998 Sep 12;317(7160):691-2
     </refsource>
     <pmid version="1">
      9732333
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      BMJ 1999 Jan 2;318(7175):29
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic beta-Antagonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Albuminuria
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Angiotensin-Converting Enzyme Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antihypertensive Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Atenolol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Blood Glucose
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Captopril
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cerebrovascular Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="Y">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetic Angiopathies
     </descriptorname>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetic Retinopathy
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypertension
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypoglycemia
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Myocardial Infarction
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Compliance
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Peripheral Vascular Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Proteinuria
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Visual Acuity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Weight Gain
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC28659
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9732337
    </articleid>
    <articleid idtype="pmc">
     PMC28659
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

